ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

Compare
Equity
Direct
Sector - Healthcare

NAV: ₹ 20.8 as on 05-12-2022

Fund Performance
zero opening, trading, fund transfer fee
1091 people have invested ₹ 37.7L in mutual fund in the last three months

INDmoney Rank

Powered by IND quant engine
IND ranking is not available for this fund.
Pros
3Y returns in the top 25% of the category
Larger AUM within category
Cons
No bad points found for this fund.

Fund Performance

Return
1M
3M
6M
1Y
3Y
This Fund
-0.7%
4.7%
8.5%
0.2%
25.6%
Benchmark
2.8%
4.4%
13.4%
7.5%
17.8%
Category
-1.6%
5.8%
8.6%
-3%
23.5%
About the Fund

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund. This fund was started on  12 July, 2018. The fund is managed by Dharmesh Kakkad, Sharmila D’mello. The fund could potentially beat inflation in the long-run.

Key parameters

1) ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has a NAV of 20.84 as on 05-12-2022.

2) ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has 2598 Cr worth of assets under management (AUM) as on 31-10-2022 and is more than category average.

3) The fund has an expense ratio 1.2 %.

Fund Overview

Expense ratio
Expense ratio
1.2%
Benchmark
Benchmark
S&P BSE Healthcare PR
AUM
AUM
₹2598 Cr
Inception Date
Inception Date
12 July, 2018
Min Lumpsum/SIP
Min Lumpsum/SIP
₹5000/₹100
Exit Load
Exit Load
1%
Lock In
Lock In
No Lock-in
TurnOver
TurnOver
50.98%

Fund Distribution

  • Equity 97.5%
  • Debt & Cash 2.5%
Size breakup
Large cap
45.3%
Mid cap
30.6%
Small cap
21.7%

Sector Allocation

Oct'22

Sep'22

Aug'22

Health

95.7%

Financial Services

4.3%

Top Holdings

  • All
  • Equity
  • Debt & Cash
Total Holdings33
Equity Holdings30
Debt Holdings3

What changed

in last one month
  • Scheme
  • Portfolio
AUM increased by 61.5 Cr in last 1M
Oct'22 return underperformed benchmark

Change in AUM

Oct'22
₹ 2.6K Cr
Sep'22
₹ 2.5K Cr
Aug'22
₹ 2.5K Cr

Fund Returns vs Benchmark

Oct'22
2.93%
5.37%
Sep'22
1.00%
-2.51%
Aug'22
-0.45%
3.22%
Fund Return
Benchmark Return

Concentration Analysis

Fund
Oct'22
Oct'22
Aug'22
No of Holdings
33
33
32
Top 5 Company Concentration
42.2%
42.7%
41.3%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (16.6%)
Sun Pharmaceuticals Industries Ltd (15.9%)
Sun Pharmaceuticals Industries Ltd (15.1%)
No of Sectors
3
3
3
Top 5 Sectors Concentration
100%
100%
100%
Sector having highest exposure
Health (93.3%)
Health (92.6%)
Health (89.9%)

Fund Manager

Dharmesh Kakkad

Dharmesh Kakkad

Managing this fund since 2 May 2020

Top funds managed

Scheme
Annualised Returns(3Y)
Category Returns(3Y)
ICICI Prudential Equity Savings Fund Direct Growth
8.1%
9.05%
ICICI Prudential Asset Allocator Fund(FOF) Direct Plan Growth
14.39%
--
ICICI Prudential Value Discovery Fund Direct Plan Growth
26.53%
20.27%
Sharmila D’mello

Sharmila D’mello

Managing this fund since 31 July 2022

Top funds managed

Scheme
Annualised Returns(3Y)
Category Returns(3Y)
ICICI Prudential Balanced Advantage Fund Direct Plan Growth
12.72%
11.65%
ICICI Prudential Bluechip Fund Direct Plan Growth
18.45%
16.17%
ICICI Prudential Value Discovery Fund Direct Plan Growth
26.53%
20.27%

AMC details

Address
ICICI Prudential Asset Mgmt.Company Limited,3rd Floor, Hallmark Business Plaza,,Sant Dyaneshwar Marg,,Bandra (East)
Phone
+912226428000
Fund House
ICICI Prudential Asset Management Company Limited

Fund Highlights

meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 18.16% since inception which is more than its category average return of 17.95%
Fund Allocations

Fund Allocations

This fund has an allocation of 97.5% in Equity, 0% in Debt and 2.5% in Cash related instruments
AUM size ₹2598 Cr

AUM size ₹2598 Cr

This fund has AUM of ₹2598 Cr which is more than its category average of ₹ 1367 Cr
Expense Ratio 1.2%

Expense Ratio 1.2%

This fund has an expense ratio of 1.2% which is less than its category average expense ratio of 1.52%

Frequently Asked Questions

The current NAV of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is 20.91.
Existing (Absolute + CAGR)
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
-1.13%
-1.13%
6 Month Returns
8.17%
8.17%
1 Year Returns
-0.1%
-0.1%
3 Years Returns
98.01%
25.57%
5 Years Returns
0%
0%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
1.2 as on November 2022
2598 Cr as on November 2022
Sun Pharmaceuticals Industries Ltd(16.64%),Dr Reddy's Laboratories Ltd(9.33%),Lupin Ltd(7.45%),Alkem Laboratories Ltd(4.89%),Aurobindo Pharma Ltd(3.87%) as on November 2022
Health(93.31%),Financial Services(4.18%),Cash Equivalent(2.5%) as on November 2022
The alpha ratio for the ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
3.18
3.63
-
As on month end.
The alpha for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
0.86
0.96
-
As on month end.
The Beta for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
-0.34
0.95
-
As on month end.
The sharpe ratio for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
13.94
21.77
-
As on month end.
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
2.29
0.92
Dharmesh Kakkad,Sharmila D’mello are the fund managers of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
The Exit load of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is 1%

Mutual Fund execution provided by

Technology facilitation Services provided by Finzoom Investment Advisors Pvt. Ltd. - Advisory unit. SEBI Registered Investment Advisor: INA100012190 | BASL Registration No. 1154 | BSE StarMF Platform code: 24801

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme related documents carefully. Past performance is not indicative of future returns.